Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer

Novo Nordisk (NYSE: NVO) stock has fallen 28% this year as investors fear that it's falling behind in the competitive GLP-1 market. The company still has some incredible blockbuster drugs in its portfolio, including Ozempic and Wegovy, but it expects its revenue to decline this year as a result of rising competition. Recently, however, the company received some great news from regulators, with the approval of a higher-dose version of Wegovy, which it will simply call Wegovy HD. While it may seem like a sm ...